December: Modern Drug Discovery: Computational Biologists Test Their New Algorithms For Predicting Protein Structure

11/27/00
The Scientist:
The State of Bioinformatics
Bioinformatics, Genomics, and Proteomics

11/08/01
Signals Magazine: Protein Chip Challenges

10.26.00    Genomic Solutions dedicate new proteomic center Full Text

10.26.00    Medichem prices IPO of 6 million shares at $45M  Full Text
Protein structures identified through MediChem's proprietary proteomics services and technologies are the basis for the identification of novel drug targets. Our proteomics and computational chemistry offerings are key components in bridging the gap between genomic information and chemistry services necessary to identify new lead compounds with the most desirable action. 

10.24.00    Large Scale Biology Corp have patent 6,136,173 issue. Patent
Title: Automated system for two-dimensional electrophoresis
Abstract:The present invention provides an integrated, fully automated, high-throughput system for two-dimensional electrophoresis comprised of gel-making machines, gel processing machines, gel compositions and geometries, gel handling systems, sample preparation systems, software and methods. The system is capable of continuous operation at high-throughput to allow construction of large quantitative data sets. 

10.17.00    Novartis Pharma AG and Geneva Proteomics, Inc. (GeneProt|) today announced that they have formed an alliance in proteomics to discover novel therapeutics, targets and biomarkers. Over the course of the collaboration, GeneProt will analyze the protein profile (proteome) of three human diseased tissues or body fluids and their healthy counterparts. Novartis will make a total equity investment of USD 43 Million and will become GeneProt's preferred pharmaceutical partner. This investment will contribute to the expansion of GeneProt's staff over the next few months. The effectiveness of the transaction is subject to receipt of regulatory approval. Full Text

10.17.00    Myriad Genetics, Inc. (Nasdaq: MYGN) announced today that it has introducedProSpec|, a powerful new drug target identification and validation technology. This new proteomics technology complements the disease pathway discovery capability of Myriad's ProNet| technologies with the use of mass spectrometry to identify protein complexes. Complexes of interacting proteins are required for
virtually all biological processes in the cell. The unique combination of Myriad's ProNet version of yeast two-hybrid and mass spectrometry technologies creates an unparalleled tool for drug discovery and development. Full Text

10.9.00    CuraGen Corporation (Nasdaq: CRGN), an integrated genomics-based drug discovery and development company, announced today that it has licensed five drug targets to Biogen, Inc., marking the completion of the research portion of their discovery collaboration. These targets were identified using CuraGenes integrated platform of functional genomic technologies, and were delivered under the terms of the original collaborative agreement. Full Text

10.9.00    CuraGen Corporation (Nasdaq: CRGN), an integrated genomics-based drug discovery and development company, announced today that it has filed a Form S-3 shelf registration statement with the Securities and Exchange Commission for the sale of up to $500 million of various types of securities. Full Text

10.3.00     Hybrigenics, the leading functional proteomics company announced today the completion of a new round of capital funding for an amount of Euro 19,5M ($17,3M). This private placement is one of the largest ever-raised in France for a biotechnology company. In addition to the current investors Apax Partners (France), Auriga (France), IMH (Germany) and HealthCap (Sweden), several other renown investors joined the company: Alafi capital(USA), Lombard Odier (Switzerland), Rendex N.V. (Belgium), Sofindev (Belgium) and Medicis AG (Germany). Full Text

Proteomics An Overview and Analysis of Current and Emerging Technologies, Competitive Landscape and the Market Environment

10.1.00    The Scientist Now That's Service Proteomics gets a boost with BD Transduction Laboratories' PowerBlot(tm) Western Array Screening Service by Barbara A. Cunningham   
Microarray enthusiasts take note: It is now possible to study relative changes in the expression levels of hundreds of proteins simultaneously thanks to the new PowerBlot Western Array Screening Service offered by BD Transduction Laboratories, a division of BD Biosciences located in Lexington, Ky. With an approach that complements the current nucleic acid methods for monitoring gene expression, this novel service analyzes cellular changes on the protein level and provides a powerful tool for proteomic studies.

9.29.00    Biotech offering Ciphergen doubled to $32, up $16 for the day, after raising $88 million Thursday night.The company is in the proteomics sector, which concerns the study of proteins and how they change during disease. Full Text

9.28.00    Ciphergen Biosystems, Inc. (CIPH) Prices IPO of 5.50 Million Shares at $16.00 Full Text

9.27.00    Sydney-based Proteome Systems has completed a capital raising campaign that has increased the company's valuation to $166 million. This additional capital will assist in the company maintaining a leadship position in the current proteomics market and to continue funding research and development to develop the next-generation of proteome analysis platforms. Directors of the company include Keith Williams, the founder of the Australian Proteome Analysis Facility (APAF), and Marc Wilkins who is credited for coining the term "proteome" in 1995. Press Release

9.27.00    Wired.com Protein Fiends Join the Fold by Andy Patrizio
To better understand how proteins fold in the hopes of discovering possible cures for illnesses, Stanford University's Pande Group is hoping for the help of the masses by taking the same approach as SETI@Home, Entropia, and Distributed Sciences: It's seeking Internet users willing to put their idle PCs to work running a massively distributed simulation. Only a week old, the Folding@Home program is designed to run simulations of how proteins assemble themselves.

9.27.00    InformedInvestor.com BioTalk from the Beltway
We again look at Emerging BioTech, this week from the perspective of proteomics. This field is the logical next step after genomics and may see similar growth. Guests are Dr. Stefan Unger, Director of Drug Discovery at Frost and Sullivan; Mats Johnson VP of Proteomics at Amersham Pharmacia BioTech; Bob Erwin, CEO of Large Scale Biology Corp.; and Jeff Williams, CEO of Genomic Solutions.

9.27.00    Genomic Solutions Inc. (Nasdaq: GNSL), a leading, worldwide supplier of automated solutions for genomic and proteomic research, announces the opening of its new, state-of-the-art Proteomic Center located at the Ann Arbor headquarters.Full Text

9.26.00 Xerion Pharmaceuticals GmbH announces Joint Venture with T.I.L.L. Photonics GmbH to develop a new MicroCALI technology

9.26.00    Proteome, Inc., a leading provider of biological knowledge-based products to the pharmaceutical and biotechnology industry, announced today that it has expanded its agreement with Merck & Co., Inc. (NYSE:MRK) to include access to Proteome's newest databases for human genome research. Under the expanded agreement, Merck will obtain access to the Human Proteome Survey Database (HumanPSDª), a broad survey of knowledge for human, mouse, and rat proteins. Full Text

9.26.00    Myriad Genetics, Inc. (Nasdaq: MYGN) announced today that it has discovered a novel drug target for the treatment of human infection by the hepatitis B virus  (HBV).  The target was discovered using Myriad's ProNet¨ proteomics technology to investigate the viral-human protein interactions. Full Text

9.23.00    Wired.com Protein and the Lean Machine by Kristen Philipkoski
"The challenge is that although the human genome was complicated, it pales in comparison to what we need to do in proteomics," Martin said. "The reason people want to take the challenge is because although the human genome sequence is the basis of human biology, it doesn't tell you what's happening in the cell at any given time. Proteins do."

9.22.00    San Francisco Chronicle Biotech Investors Take a Look at Proteomics Bay Area companies playing a key role in emerging field by Tom Abate
Even as the hype about the human genome subsides, daring investors are talking about the next big thing in biotechnology -- the effort to understand the millions of proteins that cause or cure disease. Today, nearly 200 money managers, investment bankers and industry executives wrap up a two-day conference in San Francisco on investment opportunities in a new field called proteomics (pro-tee-OH- micks). 

9.19.00    Compugen Ltd. announced today the commercial availability of its Z3 high throughput 2D gel electrophoresis analysis system. Z3 is Compugen's first product for proteomics research. Full Text

9.19.00    PE Biosystems Group, a PE Corporation business now conducting business under the Applied Biosystems name, and Oxford GlycoSciences Plc (LSE: OGS) today announced they have signed an agreement for OGS to become an early access customer for Applied Biosystems' next-generation MALDI TOF/TOF mass spectrometer. Full Text

9.14.00    Proteome, Inc., a leading provider of biological knowledge-based products to the pharmaceutical and biotechnology industry today announced a key strategic collaboration for advancing biology with Celera Genomics, a PE Corporation business. Proteome's BioKnowledge Library, which includes human, worm and yeast annotation, will be linked and distributed through the Celera Discovery System. Full Text

9.14.00    Gemini Genomics, the clinical genomics company, today announced that in collaboration with Large Scale Biology Corporation, they have successfully isolated in excess of 70 proteins associated with the development of major chronic diseases, including osteoporosis, osteoarthritis, obesity, diabetes, and cardiovascular disease. The proteins were discovered as part of a multi-disease alliance between the two companies formed in February 1999, utilizing Gemini's extensive collection of human clinical samples in conjunction with LSBC's highly industrialized proteomics technology. Full Text

9.12.00    Proteome, Inc., a leading provider of biological knowledge-based products to the pharmaceutical and biotechnology industry, today announced that it has launched the first human databases coupling protein functional information to the human genome. Full Text

9.12.00    AxCell Biosciences Corporation, a wholly owned subsidiary of Cytogen Corporation (Nasdaq: CYTO) today announced that it has achieved its goal for high-throughput measurement of protein interactions. AxCell researchers have integrated a series of automated and proprietary, laboratory procedures involving cloning, robotic sample manipulation, and computerized data recording into a sustainable, high-throughput commercial process. On a daily basis, scientists can measure approximately 10,000 protein-protein interactions. Full Text

8.28.00    PE Biosystems Group (NYSE:PEB), a PE Corporation business now doing business under the Applied Biosystems name, announces, through its Applied Biosystems/MDS SCIEX joint venture, the next progression in mass spectrometry systems for proteomics researchers.The optional oMALDIª ion source for the API QSTARª Pulsar Hybrid LC/MS/MS System would, for the first time, enable customers to perform higher-throughput analysis of peptides and proteins with high sensitivity and mass accuracy as routine applications. Full Text

8.18.00    Wired.com Bio Gets Big Blue's Big Bucks by Kristen Philipkoski
IBM supplies several supercomputers to biology-focused companies, and is creating Blue Gene, a supercomputer that will be 100 times faster than any available today, the company says, and designed to help researchers better understand proteins.  

8.4.00    Genomic Solutions Inc. (Nasdaq: GNSL), a leading, worldwide supplier of automated solutions for genomic and proteomic research, has introduced Investigator^TM High Throughput 2-D electrophoresis analysis PC software. Full Text

7.26.00    Proteome Systems Limited and CSIRO Australia today announced the signing of an agreement to develop opportunities for research collaboration in the cutting-edge fields of proteomics and bioinformatics."Identifying the structure and functions of proteins is a hugely valuable undertaking. This is what we call proteomics," says Dr Keith Williams, CEO of Proteome Systems. Full Text

7.25.00    PE Biosystems (NYSE: PEB), a PE Corporation business now conducting business under the name Applied Biosystems, announced today a collaboration with the Ludwig Institute for Cancer Research to create a unified, state-of-the-art informatics infrastructure needed for emerging high-throughput proteomics laboratories. The collaboration will allow scientists from Ludwig InstituteÕs London UC Branch to take full advantage of a complete proteomics solution, using Applied Biosystems market-leading high-throughput instruments, reagents and software. Full Text

7.12.00    AxCell Biosciences Corporation, a wholly owned subsidiary of Cytogen Corporation (Nasdaq: CYTO), has agreed to form a collaboration with the Institute for Systems Biology (ISB), a newly founded research center in Seattle headed by Dr. Leroy Hood. Initially, the two groups plan to work together to chart the protein-interaction changes in prostate cells that have become cancerous. In the future, the collaboration plans to examine other forms of cancer and other diseases that are believed to be caused by defects in protein-to-protein signaling within cells. Full Text

July 11    Packard BioScience Announces Issuance of Key Biochip Production Patents

7.03.00    Time Magazine The Next Frontier: Proteomics by Unmesh Kher
Even before they finished decoding the human genome, scientists began the next and far more challenging step in explaining the molecular underpinnings of life. It's called proteomics--the cataloging and analysis of every protein in the human body.

July 10    Ciphergen¨ Biosystems, Inc. Announces Opening of First Biomarker Discovery Centerª

6.27.00    The New York Times Now, the Hard Part: Putting the Genome to Work by Nicholas Wade
Understanding the role of every human protein--proteomics--will be one of the goals of the post-genome era.

June 26 Xerion Pharmaceuticals GmbH awarded EU grant on neural phosphatases

June 21  GeneFormatics to Identify Novel Therapeutic Targets for Schering-Plough Research Institute

June 21    Spotfire and Proteome Partner to Deliver Premier Genomics and Proteomics Discovery Platform

June 20    ProteoMetrics, LLC announces a new interface for protein identification

June 19 CYTOGEN'S AxCell Biosciences Achieves Initial Proteomics Automation

June 13    DoubleTwist Releases Version 4.0 of Industry-Leading Gene Clustering and Alignment Tools; Announces Distribution Alliance with Hitachi, Ltd to Market CAT and Prophecyª Products in Asia-Pacific

June 12    Businessweek: The Genome Gold Rush 

                "Some companies, working on the proteins rather than the genes, have created an entire new field, called proteomics. Their aim is to find and understand the estimated 1 million human proteins. Leading this booming new field are companies like Myriad Genetics, Cytogen, and CuraGen."

6.12.00    The Scientist Pursuing Proteomes
Large-scale protein profiling studies reveal the molecular bases of cellular processes and disease states

June 9    Biovation signs research agreement withTanox

June 6    Curagen establishes 454 Corporation

June 1   Proteome, Inc. and Doubletwist announce partnership

May 31    Myriad Genetics discovers 2 novel proteins in pharmacia collaboration

May 22 Xerion Pharmaceuticals GmbH conducts pilot project with Aventis to validate cardiovascular and metabolic disease targets

May 24     Cytogen awarded core proteomics patent (Australian Patent No. 711141)

May 10    Myriad Genetics and Hitachi Establish Strategic Proteomics Alliance

May 10    Curagen receives patent covering high-throughput proteomics technology 

May 4    Genomic Solutions Announces New Proteomic Center

May 3    Lynx Therapeutics, Inc. and Hybrigenics S.A. of Paris, France, announced today they have entered into a collaboration

April 28     AxCell Biosciences Corporation, a wholly owned subsidiary of Cytogen Corporation today announced that it had achieved two key milestones in its collaboration with InforMax, Inc

April 10    Vertex Pharmaceuticals Inc. announced that it has entered into an agreement with Harvard Medical School to accelerate small molecule drug discovery using genomic and proteomic information from Harvard Medical School's Institute of Proteomics

March 14    Lynx Therapeutics, Inc. registers for IPO

March 22    Oxford GlycoSciences announced that it has filed patents for more than 800 different protein-use combinations.

March 21     Ciphergen Biosystems, Inc. files with the SEC for initial public offering (IPO) of common stock. 

March 21    GeneData AG enters agreement with Teijin Systems Technology Ltd. to provide bioinformatics support for proteomics research.

March 15     PE Biosystems (NYSE: PEB) announced the formation of a proteomics research center at its PerSeptive Biosystems Division

March 15     Celera Genomics and PE Biosystems  anounce proteomics collaboration

Feb. 29         Proteome, Inc receives $8.1 million in first round financing

Feb. 28        UroGenesys, Inc. and Protein Pathways, Inc. announced today an alliance to apply Protein Pathways' proteomics bioinformatics technologies to UroGenesys' proprietary database of cancer-associated antigens. 

Feb. 8         proteomics-related patent US6023659 issues. Owned by Incyte Genomics 

2.07.00    The Scientist Proteomics Factories: High-throughput techniques will likely change the field of structural biology by Eugene Russo
Thus the stage has been set for what could become a Human Proteomics Project, a collaboration involving several labs churning out not sequences, but atomic structures using NMR spectroscopy and X-ray crystallography.

Feb. 1        Protana starts proteomics project studying the pathogenic microorganisms Helicobactrer pylori (H. pylori) and Mycobacterium tuberculosis (M. tuberculosis)

Feb.         Genomic Solutions files with the SEC for initial public offering (IPO) of common stock.

Jan. 25     Proteomics-related patent US6013165 issues. Owned by Lynx Therapeutics, Inc (US)

Copyright © 2004 ProteinScience.com. All rights reserved.
ProteinScience.com is not affiliated with Protein Sciences, Inc. or the journal Protein Science.